BioSpace News Archive

Business

Zimmer Biomet Reports Third Quarter 2017 Financial Results

Diluted earnings per share for the quarter were $0.48, a decrease of 38.5% from the prior year period.

November 1, 2017

·

60 min read

Business

Sigilon Therapeutics Appoints Eric Shaff to Board of Directors

Sigilon today announced the appointment of Eric Shaff, CFO of Seres, to the Sigilon board of directors.

November 1, 2017

·

2 min read

Business

Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017

Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

November 1, 2017

·

2 min read

Biotech Bay

DiscGenics Joins MedCision’s ThawSTAR Early Adopter Program for Cell Therapy Clinical Trials

The program was initiated to help companies and investigators de-risk thawing of frozen cell therapies in early stage clinical trials through to commercialization and point-of-care.

November 1, 2017

·

3 min read

Genetown

Symbiotix Biotherapies Receives $5 Million in Institutional Financing to Advance Its Development of Molecular Therapeutics that Modulate Regulatory T Cell Activity

Symbiotix Biotherapies announced the completion of $5 million in institutional financing from Kairos Ventures, LLC.

November 1, 2017

·

3 min read

Business

Natera Chosen for Longitudinal Circulating Tumor DNA Study in Breast Cancer

Natera has entered into a research collaboration with Imperial College London and the University of Leicester, U.K., to leverage the company’s Signatera personalized ctDNA technology to evaluate retrospectively the use of ctDNA to detect disease recurrence in women breast cancer patients.

November 1, 2017

·

6 min read

Business

Purdue Pharma Joins the Prescription Drug Safety Network

The course includes interactive sessions and self-guided activities to empower students with knowledge, skills, and strategies to help prevent prescription drug misuse and abuse.

November 1, 2017

·

4 min read

Biotech Bay

Quark Pharmaceuticals Phase II Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

Quark announced that Phase 2 data on its lead program QPI-1002 will be presented as an oral abstract at the American Society of Nephrology (ASN) / Kidney Week being held in New Orleans, LA from October 31 through November 5, 2017.

November 1, 2017

·

4 min read

Business

Tenaya Therapeutics Appoints Tim Hoey, Ph.D. as CSO

Dr. Hoey is a biopharmaceutical executive with over two decades of experience in the industry.

November 1, 2017

·

2 min read

Drug Development

Theravance Biopharma and Mylan Report Additional Positive Phase III Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting

James F. Donohue, MD, Professor of Medicine, Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill, presented new data from the completed three-month Phase III studies.

November 1, 2017

·

15 min read